Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 7825 - 7832 of 12038 results
Changes to Lease Accounting Rules (Seminar September 15, 2016)
September 9, 2016| Blog| Viewpoint
Minor League Baseball Players Strike Out in Attempt to Certify Class for Wage Claims
September 9, 2016| Blog| Viewpoint
2018 Notice of Benefits and Payment: Proposed Updates to the HHS Risk Adjustment Model
September 8, 2016| Blog| Viewpoint
Back to School – Avoiding Theft of Data and Money via the “Business Email Compromise” Scam
September 8, 2016| Blog| Viewpoint
Medicaid Managed Care Transitions' Impact on Brain Injury Waiver Populations
September 8, 2016| News
GAO Report Suggests Discount Coupons Impact Medicare Spending for Part B Drugs
September 7, 2016| Blog| Viewpoint
Welcome Back: New York State Gaming Commission Issues Temporary Permits to Five Daily Fantasy Operators
September 7, 2016| Blog| Viewpoint
First Monday in October Might be Big Day for College Athletes
September 7, 2016| Blog| Viewpoint
News & Press Releases
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|